NASDAQ:TBIO Telesis Bio (TBIO) Stock Price, News & Analysis $3.98 +0.06 (+1.53%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.98▼$4.1050-Day Range$3.03▼$4.9952-Week Range$3.03▼$29.34Volume3,774 shsAverage Volume39,054 shsMarket Capitalization$6.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends Get Telesis Bio alerts: Email Address Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Telesis Bio Stock (NASDAQ:TBIO)Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.Read More TBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TBIO Stock News HeadlinesMay 10, 2024 | investorplace.comTBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comTelesis Bio Reports First Quarter 2024 Financial ResultsJuly 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.May 6, 2024 | globenewswire.comTelesis Bio Announces Reverse Stock SplitApril 20, 2024 | uk.investing.comTelesis Bio appoints new CEO as founder steps downApril 18, 2024 | msn.comTelesis Bio announces leadership transition amid new commercial focusApril 18, 2024 | globenewswire.comTelesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadershipMarch 29, 2024 | msn.comTBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q4 2023July 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.March 28, 2024 | globenewswire.comTelesis Bio Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 3, 2024 | morningstar.comTelesis Bio Inc TBIOFebruary 26, 2024 | finance.yahoo.comTelesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial ResultsFebruary 26, 2024 | globenewswire.comTelesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial ResultsFebruary 24, 2024 | benzinga.comTelesis Bio Stock (NASDAQ:TBIO), Insider Trading ActivityFebruary 23, 2024 | investorplace.comWhy Is Telesis Bio (TBIO) Stock Up 29% Today?February 23, 2024 | msn.comToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayFebruary 18, 2024 | finance.yahoo.comTelesis Bio, Inc. (TBIO)February 6, 2024 | finance.yahoo.comTelesis Bio, Inc.'s (NASDAQ:TBIO) Shares Leap 38% Yet They're Still Not Telling The Full StorySee More Headlines Receive TBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:TBIO Previous SymbolNASDAQ:DNAY CUSIPN/A CIK1850079 Webtelesisbio.com Phone858-228-4115FaxN/AEmployees137Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($28.1817) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,720,000.00 Net Margins-183.66% Pretax Margin-183.57% Return on Equity-359.32% Return on Assets-38.33% Debt Debt-to-Equity Ratio22.76 Current Ratio3.65 Quick Ratio3.08 Sales & Book Value Annual Sales$27.51 million Price / Sales0.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book28.79Miscellaneous Outstanding Shares1,680,000Free Float1,271,000Market Cap$6.77 million OptionableOptionable Beta1.74 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Eric Esser (Age 55)President, CEO, COO & Director Comp: $429.11kDr. Todd R. Nelson MBA (Age 57)Ph.D., Founder & Director Comp: $621.61kMr. Robert H. Cutler (Age 56)Chief Legal Officer Comp: $413.34kMr. William J. Kullback (Age 64)Chief Financial Officer Mr. Daniel G. Gibson Ph.D. (Age 47)Chief Technology Officer Comp: $590.37kMs. Jen CarrollVice President of Investor RelationsMr. Decky Goodrich M.B.A.Senior Vice President of Corporate DevelopmentRichard LepkeDirector of Investor RelationsMore ExecutivesKey CompetitorsAccelerate DiagnosticsNASDAQ:AXDXSingular Genomics SystemsNASDAQ:OMICTalis BiomedicalNASDAQ:TLISAstrotechNASDAQ:ASTCPrecipioNASDAQ:PRPOView All Competitors TBIO Stock Analysis - Frequently Asked Questions How have TBIO shares performed this year? Telesis Bio's stock was trading at $7.1820 at the start of the year. Since then, TBIO stock has decreased by 44.6% and is now trading at $3.98. View the best growth stocks for 2024 here. How were Telesis Bio's earnings last quarter? Telesis Bio, Inc. (NASDAQ:TBIO) announced its earnings results on Thursday, May, 9th. The company reported ($99.28) earnings per share (EPS) for the quarter. The business had revenue of $3.44 million for the quarter, compared to analysts' expectations of $6.90 million. Telesis Bio had a negative trailing twelve-month return on equity of 359.32% and a negative net margin of 183.66%. When did Telesis Bio's stock split? Telesis Bio shares reverse split on Thursday, May 9th 2024. The 1-18 reverse split was announced on Thursday, May 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What is Craig J. Tuttle's approval rating as Telesis Bio's CEO? 13 employees have rated Telesis Bio Chief Executive Officer Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among the company's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Telesis Bio IPO? Telesis Bio (TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO. How do I buy shares of Telesis Bio? Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Telesis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Telesis Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA) and Johnson & Johnson (JNJ). This page (NASDAQ:TBIO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telesis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.